[1] [2] Fox KA, Clayton TC, Damman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435−2445. doi: 10.1016/j.jacc.2010.03.007 [3] Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018; 391: 31−40. doi: 10.1016/S0140-6736(17)32714-9 [4] Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503−1516. doi: 10.1056/NEJMoa070829 [5] Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020; 382: 1395−1407. doi: 10.1056/NEJMoa1915922 [6] Nanna MG, Chen ST, Nelson AJ, et al. Representation of older adults in cardiovascular disease trials since the inclusion across the lifespan policy. JAMA Intern Med 2020; 180: 1531−1533. doi: 10.1001/jamainternmed.2020.2750 [7] Inohara T, Kohsaka S, Spertus JA, et al. Comparative trends in percutaneous coronary Intervention in Japan and the United States, 2013 to 2017. J Am Coll Cardiol 2020; 76: 1328−1340. doi: 10.1016/j.jacc.2020.07.037 [8]

Rao SV, Vidovich MI, Gilchrist IC, et al. 2021 ACC expert consensus decision pathway on same-day discharge after percutaneous coronary intervention. J Am Coll Cardiol 2021; 77: 811−825.

[9] Almarzooq ZI, Wadhera RK, Xu J, Yeh RW. Population trends in rates of percutaneous coronary interventions, 2010 to 2017. JAMA Cardio 2021; 6: 1219−1220. doi: 10.1001/jamacardio.2021.2639 [10] [11] Alkhouli M, Alqahtani F, Kalra A, et al. Trends in characteristics and outcomes of patients undergoing coronary revascularization in the United States, 2003-2016. JAMA Netw Open 2020; 3: e1921326. doi: 10.1001/jamanetworkopen.2019.21326 [12] Doshi R, Patel N, Kalra R, et al. Incidence and in-hospital outcomes of single-vessel coronary chronic total occlusion treated with percutaneous coronary intervention. Int J Cardiol 2018; 269: 61−66. doi: 10.1016/j.ijcard.2018.07.075 [13] Goel K, Gupta T, Kolte D, et al. Outcomes and temporal trends of inpatient percutaneous coronary intervention at centers with and without on-site cardiac surgery in the United States. JAMA Cardiol 2017; 2: 25−33. doi: 10.1001/jamacardio.2016.4188 [14] Dodson JA, Geda M, Krumholz HM, et al. Design and rationale of the comprehensive evaluation of risk factors in older patients with AMI (SILVER-AMI) study. BMC Health Serv Res 2014; 14: 506. doi: 10.1186/s12913-014-0506-4 [15] Nanna MG, Navar AM, Wang TY, et al. Statin use and adverse effects among adults > 75 years of age: insights from the patient and Provider Assessment of Lipid Management (PALM) Registry. J Am Heart Assoc 2018; 7: e008546. doi: 10.1161/JAHA.118.008546 [16]

Nanna MG, Peterson ED, Wojdyla D, Navar AM. The accuracy of cardiovascular pooled cohort risk estimates in U. S. older adults. J Gen Intern Med 2020; 35: 1701−1708.

[17]

Díez-Villanueva P, Méndez CJ, Alfonso F. Non-ST elevation acute coronary syndrome in the elderly. J Geriatr Cardiol 2020; 17: 9−15.

[18] Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet 2018; 391: 1775−1782. doi: 10.1016/S0140-6736(18)30668-8 [19]

Gilbert T, Cordier Q, Polazzi S, et al. External validation of the Hospital Frailty Risk Score in France. Age Ageing 2021; 51: afab126.

[20] Kilkenny MF, Phan HT, Lindley RI, et al. Utility of the hospital frailty risk score derived from administrative data and the association with stroke outcomes. Stroke 2021; 52: 2874−2881. doi: 10.1161/STROKEAHA.120.033648 [21] Kini V, Peterson PN, Spertus JA, et al. Clinical model to predict 90-day risk of readmission after acute myocardial infarction. Circ Cardiovasc Qual Outcomes 2018; 11: e004788. doi: 10.1161/CIRCOUTCOMES.118.004788 [22] Song Z, Blumenthal DM. Expanding payment reform in medicare: the cardiology episode-based payment model. JAMA 2016; 316: 1973−1974. doi: 10.1001/jama.2016.16146 [23] Brennan JM, Curtis JP, Dai D, et al. Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: results From 1, 208, 137 Procedures in the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv 2013; 6: 790−799. doi: 10.1016/j.jcin.2013.03.020 [24] Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: Results in 7, 472 octogenarians. J Am Coll Cardiol 2000; 36: 723−730. doi: 10.1016/S0735-1097(00)00777-4 [25]

Numasawa Y, Inohara T, Ishii H, et al. Comparison of outcomes after percutaneous coronary intervention in elderly patients, including 10 628 nonagenarians: insights from a Japanese Nationwide Registry (J-PCI Registry). J Am Heart Assoc 2019; 8: e011183.

[26] Niebauer J, Sixt S, Zhang F, et al. Contemporary outcome of cardiac catheterizations in 1085 consecutive octogenarians. Int J Cardiol 2004; 93: 225−230. doi: 10.1016/S0167-5273(03)00216-X [27]

Damluji AA, Ramireddy A, Otalvaro L, Forman DE. Secondary cardiovascular prevention in older adults: an evidence based review. J Geriatr Cardiol 2015; 12: 459−464.

[28] Nanna MG, Hajduk AM, Krumholz HM, et al. Sex-based differences in presentation, treatment, and complications among older adults hospitalized for acute myocardial infarction: The SILVER-AMI Study. Circ Cardiovasc Qual Outcomes 2019; 12: e005691. doi: 10.1161/CIRCOUTCOMES.119.005691 [29] Sawant AC, Josey K, Plomondon ME, et al. Temporal trends, complications, and predictors of outcomes among nonagenarians undergoing percutaneous coronary intervention: insights from the veterans affairs clinical assessment, reporting, and tracking program. JACC Cardiovasc Interv 2017; 10: 1295−1303. doi: 10.1016/j.jcin.2017.03.051 [30] Zaman MJ, Stirling S, Shepstone L, et al. The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: a cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Eur Heart J 2014; 35: 1551−1558. doi: 10.1093/eurheartj/ehu039 [31] An S, Ahn C, Moon S, et al. Individualized biological age as a predictor of disease: Korean Genome and Epidemiology Study (KoGES) Cohort. J Pers Med 2022; 12: 505. doi: 10.3390/jpm12030505 [32] Yousefzadeh MJ, Flores RR, Zhu Y, et al. An aged immune system drives senescence and ageing of solid organs. Nature 2021; 594: 100−105. doi: 10.1038/s41586-021-03547-7 [33] Kim LK, Yeo I, Cheung JW, et al. Thirty-day readmission rates, timing, causes, and costs after st-segment-elevation myocardial infarction in the United States: a national readmission database analysis 2010-2014. J Am Heart Assoc 2018; 7: e009863. doi: 10.1161/JAHA.118.009863 [34] Teplitsky I, Assali A, Lev E, et al. Results of percutaneous coronary interventions in patients ≥ 90 years of age. Catheter Cardiovasc Interv 2007; 70: 937−943. doi: 10.1002/ccd.21263 [35] Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59: M255−M263. doi: 10.1093/gerona/59.3.M255 [36] Murali-Krishnan R, Iqbal J, Rowe R, et al. Impact of frailty on outcomes after percutaneous coronary intervention: a prospective cohort study. Open Heart 2015; 2: e000294. doi: 10.1136/openhrt-2015-000294 [37]

Wang P, Zhang S, Zhang K, Tian J. Frailty predicts poor prognosis of patients after percutaneous coronary intervention: a meta-analysis of cohort Studies. Front Med (Lausanne) 2021; 8: 696153.

[38] Dodson JA, Hajduk AM, Murphy TE, et al. Thirty-day readmission risk model for older adults hospitalized with acute myocardial infarction. Circ Cardiovasc Qual Outcomes 2019; 12: e005320. doi: 10.1161/CIRCOUTCOMES.118.005320 [39] Amarasekera AT, Chang D, Schwarz P, Tan TC. Does vascular endothelial dysfunction play a role in physical frailty and sarcopenia? A systematic review. Age Ageing 2021; 50: 725−732. doi: 10.1093/ageing/afaa237 [40]

Liu Y, Liu S, Wang K, Liu H. Association of frailty with antiplatelet response among elderly Chinese patients with coronary artery disease undergoing percutaneous coronary intervention. Clin Appl Thromb Hemost 2020; 26: 1076029620915994.

[41] Munk PS, Butt N, Larsen AI. Endothelial dysfunction predicts clinical restenosis after percutaneous coronary intervention. Scand Cardiovasc J 2011; 45: 139−145. doi: 10.3109/14017431.2011.564646 [42]

Soysal P, Arik F, Smith L, et al. Inflammation, frailty and cardiovascular disease. Adv Exp Med Biol 2020; 1216: 55−64.

[43] Kolte D, Khera S, Sardar MR, et al. Thirty-day readmissions after transcatheter aortic valve replacement in the united states: insights from the nationwide readmissions database. Circ Cardiovasc Interv 2017; 10: e004472. doi: 10.1161/CIRCINTERVENTIONS.116.004472 [44] Tripathi A, Abbott JD, Fonarow GC, et al. Thirty-day readmission rate and costs after percutaneous coronary intervention in the United States: a national readmission database analysis. Circ Cardiovasc Interv 2017; 10: e005925. doi: 10.1161/CIRCINTERVENTIONS.117.005925 [45] Tan SY, Feng JY, Joyce C, et al. Association of hospital discharge against medical advice with readmission and in-hospital mortality. JAMA Netw Open 2020; 3: e206009. doi: 10.1001/jamanetworkopen.2020.6009